Navigation Links
New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy
Date:6/13/2010

cations for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and products liability claims.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affectin
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
3. Publication in Neuropsychopharmacology Confirms CeNeRxs Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
4. Vivakor Confirms Record Date of Stock Dividend
5. New study confirms exotic electric properties of graphene
6. Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products
7. Analysis confirms that nano-related research has strong multidisciplinary roots
8. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
11. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's ... entire waste to energy process and continue to contribute to the sustainability of ... Temarry’s Waste to Energy process has been operating at their Mexico facility, Recicladora ...
(Date:9/2/2015)... ... September 02, 2015 , ... Genedata, ... research, today unveiled Genedata Screener ® version 13.0 at ELRIG Drug Discovery ... to market a rich set of new capabilities. Screener now supports High Throughput ...
(Date:9/1/2015)... ... ... Spirax Sarco , the leader in products and services for steam ... This platform, offering unique online ordering capabilities, is only available to Spirax Sarco distributors. ... Spirax Sarco Anytime and within minutes you can be making your purchase. Distributors ...
(Date:9/1/2015)... N.J. , Sept. 1, 2015  ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... & Renshaw 17 th Annual Global Investment Conference ... place September 8-10, 2015 at The St. Regis Hotel ... James Sapirstein , Chief Executive Officer, ...
Breaking Biology Technology:Temarry Recycling’s New $100,000 Waste to Energy Renovation 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4Spirax Sarco Announces New Features to Anytime Platform 2ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... Prodesse Inc. , a biotechnology company focused on the ... infectious diseases, has entered into an in-vitro diagnostics patent ... pharmaceutical firm. , ,Under the agreement, which will be ... Roche enzymes in its products. Prodesse also receives the ...
... first half stock market doesn't look pretty! The Dow is up ... that level but took a tumble in May falling sharply in ... really taken a hit in these first 6 months, having dropped ... again surpassing the $3/gallon level. This time, surprisingly, American consumers seem ...
... a conference call with investors, the new executive team at ... the NASDAQ Stock Market on its request for an extension on ... Dunham, joined by interim co-CEOs Brian Pedlar and Robert White, said ... completion of a financial audit, but he made no prediction on ...
Cached Biology Technology:First half of 2006 roundup: Big Pharma trumps biotech 2First half of 2006 roundup: Big Pharma trumps biotech 3First half of 2006 roundup: Big Pharma trumps biotech 4First half of 2006 roundup: Big Pharma trumps biotech 5First half of 2006 roundup: Big Pharma trumps biotech 6No word on NASDAQ extension for Merge 2
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
(Date:8/5/2015)... Transparency Market Research has released ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... is forecast to reach US$ 2,671.8 Mn by 2022. ... systems by civil and government agencies. This is majorly ... activities across the globe that would elevate the demand ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... power for granted whenever they flip on a light switch. ... the United States makes the on-demand delivery of electricity more ... grid has virtually no storage capacity, so grid operators can,t ... when the wind isn,t blowing. To provide more flexibility ...
... at the Ruhr Universitt Bochum have developed a new ... crystals for the first time also membrane proteins. ... using infrared spectroscopy in a way that is accurate ... the EU project "Kinetics for Drug Discovery, K4DD", in ...
... villagers would benefit from fences to protect them from ... of Minnesota researcher Craig Packer published online by ... has long been anathema to most conservationists, but Packer ... African wildlife, an undertaking that will require sweeping measures ...
Cached Biology News:Stanford scientists calculate the carbon footprint of grid-scale battery technologies 2Stanford scientists calculate the carbon footprint of grid-scale battery technologies 3Stanford scientists calculate the carbon footprint of grid-scale battery technologies 4Stanford scientists calculate the carbon footprint of grid-scale battery technologies 5Specialised germanium surface as universal protein adapter 2Specialised germanium surface as universal protein adapter 3World's leading lion researcher calls for a 'Marshall Plan' for African wildlife 2
Mouse P-Selectin/CD62P MAb (Clone 127933)...
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: